Serum-Circulating microRNAs in Sporadic Inclusion Body Myositis

Int J Mol Sci. 2023 Jul 6;24(13):11139. doi: 10.3390/ijms241311139.

Abstract

Sporadic inclusion body myositis (s-IBM) represents a unique disease within idiopathic inflammatory myopathies with a dual myodegenerative-autoimmune physiopathology and a lack of an efficacious treatment. Circulating miRNA expression could expand our knowledge of s-IBM patho-mechanisms and provide new potential disease biomarkers. To evaluate the expression of selected pre-amplified miRNAs in the serum of s-IBM patients compared to those of a sex- and age-matched healthy control group, we enrolled 14 consecutive s-IBM patients and 8 sex- and age-matched healthy controls. By using two different normalization approaches, we found one downregulated and three upregulated miRNAs. hsa-miR-192-5p was significantly downregulated, while hsa-miR-372-3p was found to be upregulated more in the s-IBM patients compared to the level of the controls. The other two miRNAs had a very low expression levels (raw Ct data > 29). hsa-miR-192-5p and hsa-miR-372-3p were found to be significantly dysregulated in the serum of s-IBM patients. These miRNAs are involved in differentiation and regeneration processes, thus possibly reflecting pathological mechanisms in s-IBM muscles and potentially representing disease biomarkers.

Keywords: hsa-miR-192-5p; hsa-miR-372-3p; idiopathic inflammatory myopathy; inclusion body myositis; miRNA.

MeSH terms

  • Biomarkers
  • Circulating MicroRNA* / genetics
  • Humans
  • MicroRNAs* / metabolism
  • Myositis*
  • Myositis, Inclusion Body* / genetics

Substances

  • Circulating MicroRNA
  • MicroRNAs
  • Biomarkers